| abstract |
The present disclosure relates to recombinant T cell receptors capable of binding MAGE-A2 epitopes and nucleic acid molecules encoding the recombinant T cell receptors. In some aspects, the nucleic acid molecule further comprises a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the present disclosure relate to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule or the vector. Other aspects of the present disclosure relate to methods of using the recombinant TCR, the nucleic acid molecule, the vector, and the cell. In some aspects, the method comprises treating cancer in a subject in need thereof. |